poisar

Stocks · News reference

Veracyte Announces New Data for Decipher Prostate Genomic Classifier

Veracyte released new data from the Phase III STAMPEDE trial demonstrating that its Decipher Prostate test can predict the clinical benefit of adding abiraterone to androgen deprivation therapy for high-risk prostate cancer patients.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VCYT
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Veracyte, Inc.

    Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

    Veracyte announced new data from a Phase III STAMPEDE trial analysis showing its Decipher Prostate Genomic Classifier can predict which men with very high-risk nonmetastatic prostate cancer will benefit from adding abiraterone to androgen deprivation therapy. The retrospective analysis provides Level 1B predictive evidence, with patients having higher Decipher scores showing greater benefit (10-11% absolute reduction in distant metastasis at five years versus 2% for lower scores). The findings support broader adoption of the test for treatment-intensification decisions.

    VCYT
  3. Na

    ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

    AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.

    ANGOGMEDVCYTWST